6:24 PM
 | 
Dec 20, 2013
 |  BC Extra  |  Company News

CHMP backs subcutaneous RoActemra

Roche (SIX:ROG; OTCQX:RHHBY) said EMA's CHMP recommended approval of a subcutaneous formulation of RoActemra tocilizumab as monotherapy or in combination with methotrexate to treat moderate to...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >